GNI Group Ltd. (FRA:3G6)

Market Cap	934.73M +46.1%
Revenue (ttm)	145.80M +13.7%
Net Income	-23.05M
EPS	-0.44
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	16.50
Previous Close	16.30
Day's Range	16.50 - 16.50
52-Week Range	11.90 - 26.00
Beta	n/a
RSI	46.58
Earnings Date	May 15, 2026

About GNI Group

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 990
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3G6

Financial Performance

Financial numbers in JPY